Results 51 to 60 of about 22,236,668 (323)

Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events [PDF]

open access: yes, 2009
Epidemiological evidence has suggested a link between beta(2)-agonists and increased asthma mortality. There has been much debate about possible causal links for this association, and whether regular (daily) long-acting beta(2)-agonists are safe ...
Christopher J Cates   +5 more
core   +1 more source

Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis

open access: yesFrontiers in Oncology, 2019
Background: Comprehensive evidence comparing treatment-related adverse events (trAEs) among PD-1/PD-L1 inhibitors is unavailable.Methods: A systematic review and network meta-analysis (NMA) was conducted.
Ya-fang Huang   +3 more
doaj   +1 more source

Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis

open access: yesFrontiers in Pharmacology, 2023
Background: Anti-PD-(L)1 antibody monotherapy or in combination with VEGF(R) blockade has been applied widely for cancer treatment. Whether combination therapy increases irAEs still remains controversial.Methods: A systematic review and meta-analysis ...
Qiyu Tang   +6 more
doaj   +1 more source

Efficacy of stem cells therapy for Crohn’s fistula: a meta-analysis and systematic review

open access: yesStem Cell Research & Therapy, 2021
Background Fistulas have puzzled us all the time and stem cell therapy for it is still in its infancy. We conducted a meta-analysis and systematic review to evaluate the efficacy of stem cells and its potential mechanisms in the management of Crohn’s ...
Yantian Cao   +4 more
doaj   +1 more source

Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series.

open access: yesEuropean journal of internal medicine, 2021
OBJECTIVE Research is moving towards a more personalized management of immune-related adverse events (irAEs) due to immune checkpoint inhibitors (ICI).
C. Campochiaro   +15 more
semanticscholar   +1 more source

Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors

open access: yesJournal of Immunology Research, 2020
Immune checkpoint inhibitors (ICIs) have completely changed the treatment of cancer, and they also can cause multiple organ immune-related adverse reactions (irAEs).
Yan Xiao   +8 more
doaj   +1 more source

Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis

open access: yesOncoimmunology, 2020
Programmed cell death-1 (PD-1) and/or cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) immune checkpoint inhibitor (ICI) treatments are associated with adverse events (AEs), which may be dependent on ICI dose.
B. Shulgin   +10 more
semanticscholar   +1 more source

Predictors of rheumatic immune-related adverse events and de novo inflammatory arthritis after immune checkpoint inhibitor treatment for cancer

open access: yesArthritis & Rheumatology, 2021
To identify predictors of rheumatic immune‐related adverse events (irAEs) following immune checkpoint inhibitor (ICI) treatment for cancer.
A. Cunningham-Bussel   +14 more
semanticscholar   +1 more source

Comparative treatment-related adverse event cost burden in immune thrombocytopenic purpura

open access: yesJournal of Medical Economics, 2017
Aims: Real-world evidence on the safety profile and costs associated with immune thrombocytopenic purpura (ITP) treatment in adults is lacking. This study quantifies and compares adverse event (AE) crude rates and costs associated with ITP treatments as found in claims data.
Prina Z, Donga   +4 more
openaire   +2 more sources

Pirfenidone in idiopathic pulmonary fibrosis:expert panel discussion on the management of drug-related adverse events [PDF]

open access: yes, 2014
Pirfenidone is currently the only approved therapy for idiopathic pulmonary fibrosis, following studies demonstrating that treatment reduces the decline in lung function and improves progression-free survival.
Per M. Hellström   +56 more
core   +1 more source

Home - About - Disclaimer - Privacy